Longitudinal outcomes of iStent inject with cataract surgery compared to cataract surgery alone: real-world data from the Fight Glaucoma Blindness registry

Colin I Clement; Vuong Nguyen; Frank Howes; Jenny Danks; Vincent Lee; David Wechsler; Emily Gregory Roberts; Mark Gillies; Mitchell Lawlor

doi:10.1097/j.jcrs.0000000000001567

Longitudinal outcomes of iStent inject with cataract surgery compared to cataract surgery alone: real-world data from the Fight Glaucoma Blindness registry

J Cataract Refract Surg. 2024 Oct 11. doi: 10.1097/j.jcrs.0000000000001567. Online ahead of print.

Authors

Colin I Clement^{1

2}, Vuong Nguyen¹, Frank Howes³, Jenny Danks⁴, Vincent Lee⁵, David Wechsler⁶, Emily Gregory Roberts⁷, Mark Gillies^{1

2}, Mitchell Lawlor^{1

8}

Affiliations

¹ Save Sight Institute, University of Sydney, NSW Australia.
² Eye Associates, Sydney NSW Australia.
³ Eye and Laser Centre, Gold Coast QLD Australia.
⁴ Northern Beaches Cataract Retina Glaucoma, NSW Australia.
⁵ South West Eye Surgery, Warrnambool, Victoria Australia.
⁶ Burwood Eye Surgery, Burwood NSW Australia.
⁷ Eye Specialist Practice, Bondi Junction NSW Australia.
⁸ Sydney Eye Surgeons, Bondi Junction NSW Australia.

PMID: 39390681
DOI: 10.1097/j.jcrs.0000000000001567

Abstract

Purpose: To compare combined phacoemulsification and iStent inject to phacoemulsification alone.

Setting: Fight Glaucoma Blindness (FGB) registry - Australia.

Design: Prospective observational registry study.

Methods: Eyes that had combined phacoemulsification with iStent inject (iStent group) were compared to eyes that had phacoemulsification only (cataract alone). Primary outcome was percentage of eyes achieving >20% IOP reduction from baseline 12 months after surgery. Secondary outcomes included mean IOP and medication reduction, adverse events and secondary procedures.

Results: At 12 months the percentage of eyes achieving >20% reduction of IOP at 12 months was significantly higher in the iStent group compared to the cataract alone group (40.9% vs 30.1% p<0.001). Adverse events occurred at a low rate in both groups, and secondary IOP lowering procedures were significantly less frequent in the iStent group compared to cataract alone.

Conclusions: Real-world outcomes from the FGB registry at 12 months show phacoemulsification combined with iStent inject has higher efficacy and a reduced need for secondary IOP lowering surgery compared to phacoemulsification alone.